{
  "trial_id": "NCT00655863",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, body mass index (BMI), glycosylated hemoglobin (HbA1c), fasting plasma glucose, fasting serum triglycerides, use of metformin, use of sulfonylurea, use of nateglinide, use of repaglinide, use of statin, use of ezetimibe, Apolipoprotein E phenotype, blood pressure, hemoglobin levels, alanine transaminase levels, serum creatinine levels, total cholesterol levels, history of coronary events, history of acute metabolic diabetic complications, history of hemoglobinopathy, history of HIV infection, history of diabetic gastroparesis, history of gastric bypass surgery.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Race (NIH/OMB)",
        "Weight",
        "Height",
        "Diabetes duration"
      ],
      "remaining_candidate_features": [
        "Age",
        "glycosylated hemoglobin (HbA1c)",
        "fasting plasma glucose",
        "fasting serum triglycerides",
        "use of metformin",
        "use of sulfonylurea",
        "use of nateglinide",
        "use of repaglinide",
        "use of statin",
        "use of ezetimibe",
        "Apolipoprotein E phenotype",
        "blood pressure",
        "hemoglobin levels",
        "alanine transaminase levels",
        "serum creatinine levels",
        "total cholesterol levels",
        "history of coronary events",
        "history of acute metabolic diabetic complications",
        "history of hemoglobinopathy",
        "history of HIV infection",
        "history of diabetic gastroparesis",
        "history of gastric bypass surgery"
      ]
    },
    "processed-gen-response": "Age, sex, body mass index (BMI), glycosylated hemoglobin (HbA1c), fasting plasma glucose, fasting serum triglycerides, use of metformin, use of sulfonylurea, use of nateglinide, use of repaglinide, use of statin, use of ezetimibe, Apolipoprotein E phenotype, blood pressure, hemoglobin levels, alanine transaminase levels, serum creatinine levels, total cholesterol levels, history of coronary events, history of acute metabolic diabetic complications, history of hemoglobinopathy, history of HIV infection, history of diabetic gastroparesis, history of gastric bypass surgery."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Body Mass Index, Baseline HbA1c, Fasting Plasma Glucose, Fasting Serum Triglycerides, Systolic Blood Pressure, Diastolic Blood Pressure, Use of Lipid-lowering Therapy, Apolipoprotein E Phenotype,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Diabetes duration",
          "Baseline HbA1c"
        ],
        [
          "Fasting Plasma Glucose",
          "Fasting Plasma Glucose"
        ],
        [
          "Fasting Serum Triglycerides",
          "Fasting Serum Triglycerides"
        ],
        [
          "Use of Lipid-lowering Therapy",
          "Use of Lipid-lowering Therapy"
        ],
        [
          "Apolipoprotein E Phenotype",
          "Apolipoprotein E Phenotype"
        ]
      ],
      "remaining_reference_features": [
        "Region of Enrollment",
        "Weight",
        "Height"
      ],
      "remaining_candidate_features": [
        "Age",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Body Mass Index, Baseline HbA1c, Fasting Plasma Glucose, Fasting Serum Triglycerides, Systolic Blood Pressure, Diastolic Blood Pressure, Use of Lipid-lowering Therapy, Apolipoprotein E Phenotype"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Fasting Plasma Glucose, HbA1c, Fasting Serum Triglyceride, Systolic Blood Pressure, Diastolic Blood Pressure, Apolipoprotein E phenotype, Diabetes Duration, Prior Diabetes Treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Diabetes duration",
          "Diabetes Duration"
        ]
      ],
      "remaining_reference_features": [
        "Weight",
        "Height"
      ],
      "remaining_candidate_features": [
        "Age",
        "Fasting Plasma Glucose",
        "HbA1c",
        "Fasting Serum Triglyceride",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Apolipoprotein E phenotype",
        "Prior Diabetes Treatment."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Fasting Plasma Glucose, HbA1c, Fasting Serum Triglyceride, Systolic Blood Pressure, Diastolic Blood Pressure, Apolipoprotein E phenotype, Diabetes Duration, Prior Diabetes Treatment."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index, duration of diabetes, glycosylated hemoglobin concentration, fasting plasma glucose, fasting serum triglyceride level, systolic and diastolic blood pressure, Apolipoprotein E phenotype, history of cardiovascular disease, history of lipid-lowering therapy, use of concomitant medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index"
        ],
        [
          "Diabetes duration",
          "duration of diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Weight",
        "Height"
      ],
      "remaining_candidate_features": [
        "Age",
        "ethnicity",
        "glycosylated hemoglobin concentration",
        "fasting plasma glucose",
        "fasting serum triglyceride level",
        "systolic and diastolic blood pressure",
        "Apolipoprotein E phenotype",
        "history of cardiovascular disease",
        "history of lipid-lowering therapy",
        "use of concomitant medications."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index, duration of diabetes, glycosylated hemoglobin concentration, fasting plasma glucose, fasting serum triglyceride level, systolic and diastolic blood pressure, Apolipoprotein E phenotype, history of cardiovascular disease, history of lipid-lowering therapy, use of concomitant medications."
  }
}